Dr. Chathur Acharya has no financial or proprietary interest in the materials presented herein.
Dr. Jessica R. Allegretti is on the scientific advisory board for Finch Therapeutics and Iterative Scopes; is a consultant for Artugen, Pfizer, Takeda, Janssen, Servatus, and Pandion; and received Grant Support from Merck.
Dr. Olga C. Aroniadis has no financial or proprietary interest in the materials presented herein.
Dr. Jasmohan S. Bajaj has no financial or proprietary interest in the materials presented herein.
Dr. Thomas J. Borody has a pecuniary interest in the Centre for Digestive Diseases, where fecal microbiota transplantation is a treatment option for patients, and he has filed patents in this field.
Dr. Lawrence J. Brandt has no financial or proprietary interest in the materials presented herein.
Dr. Shrish Budree is an employee/shareholder of Finch Therapeutics.
Dr. Jennifer D. Claytor has no financial or proprietary interest in the materials presented herein.
Dr. Suzanne Devkota has no financial or proprietary interest in the materials presented herein.
Dr. Najwa El-Nachef has no financial or proprietary interest in the materials presented herein.
Dr. Paul Feuerstadt is on the speakers bureau at Merck and Co. and a consultant for Ferring Pharmaceuticals and Roche Diagnostics.
Dr. Monika Fischer is a DSMB monitoring board member for Rebiotix and OpenBiome.
Dr. Rohma Ghani has no financial or proprietary interest in the materials presented herein.
Dr. Ari M. Grinspan has no financial or proprietary interest in the materials presented herein.
Dr. Lauren Tal Grinspan has no financial or proprietary interest in the materials presented herein.
Dr. Anoja W. Gunaratne has no financial or proprietary interest in the materials presented herein.
Dr. Zain Kassam is an employee/shareholder of Finch Therapeutics.
Dr. Colleen R. Kelly receives research support from Finch Therapeutics and was a site principal investigator for the PRISM3 clinical trial.
Dr. Alexander Khoruts as research funding from Finch Therapeutics and patents pertaining to preparation and preservation of fecal microbiota for transplantation.
Dr. Joann Kwah has no financial or proprietary interest in the materials presented herein.
Dr. Neena Malik has no financial or proprietary interest in the materials presented herein.
Dr. Paul Moayyedi has no financial or proprietary interest in the materials presented herein.
Dr. Benjamin H. Mullish has received consultancy fees from Finch Therapeutics Group.
Sára Nemes has no financial or proprietary interest in the materials presented herein.
Dr. Majdi Osman is an employee of OpenBiome.
Dr. Pratik Panchal has no financial or proprietary interest in the materials presented herein.
Dr. Abbas Rupawala has no financial or proprietary interest in the materials presented herein.
Dr. Lindsey Russell has no financial or proprietary interest in the materials presented herein.
Dr. Christopher Saddler has no financial or proprietary interest in the materials presented herein.
Dr. Nasia Safdar has no financial or proprietary interest in the materials presented herein.
Dr. Neil Stollman received research grant support from Assembly Bioscience.
Related posts:
Introduction
Copyright
Frequently Asked Questions
Decision: Considerations for Use of Fecal Microbiota Transplantation in Special Patient Populations
Discussion: How Do You Discuss the Risks and Benefits of Fecal Microbiota Transplantation?
Decision: Which Patients With Clostridioides difficile Infection Are Appropriate for Fecal Microbiota Transplantation?
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
